FDA grants Breakthrough Device Designation to ReVision Implant — Occular
Med-Tech Insights, Oliver Johnson. March 9, 2026. URL: https://med-techinsights.com/2026/03/09/fda-grants-breakthrough-device-designation-to-revision-implant-visual-cortex-prosthesis/
Key facts from this article
- Designation: FDA Breakthrough Device Designation received March 2026 for Occular, the ReVision Implant visual cortical prosthesis.
- Benefit of BDD: Early feedback on regulatory roadmap, data, clinical trial protocols; access to FDA’s Total Product Life-Cycle Advisory Program (TAP) Pilot. Note: only ~160 medical devices received Breakthrough status throughout all of 2025.
- Clinical timeline (updated as of March 2026):
- First short-term clinical trial during scheduled brain surgery: October 2026 (intra-operative acute test — previously described as TTK Budapest epilepsy resection)
- Early-stage human trials in blind volunteers: summer 2027 (subject to regulatory approvals)
- Technology summary:
- Miniature camera on wireless headset → brain implant stimulates visual cortex neurons in patterns interpreted as points of light → simple visual representations.
- Bypasses retina and optic nerve entirely — applicable to any blindness cause (retinal degeneration, optic nerve damage, etc.).
- Development started 2020; >2 years of long-term animal preclinical studies completed.
- Strategy: long-term performance focus from day one (contrasted with other neurotech).
- Target population: ~650,000 people with untreatable blindness in US + EU combined (company estimate). Global tens of millions with severe vision loss.
- CEO quote (Ceyssens): “While cochlear implants have transformed treatment for hearing loss, there is still no widely available neuroprosthetic solution for restoring vision. Our aim is to provide people living with severe blindness with functional vision that improves independence and quality of life.”
Notes on confidence
This is a trade press news article. Primary facts (BDD award date, TAP Pilot access, clinical timelines) are attributed to ReVision Implant directly. Clinical timelines are company-stated targets subject to change; label as planned/expected, not confirmed.